Form 8-K MARINUS PHARMACEUTICALS, For: Aug 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
JMP Securities Reiterates Market Outperform Rating on Marinus Pharmaceuticals (MRNS)
August 13, 2024 4:09 PM EDTJMP Securities analyst Jason N. Butler reiterated a Market Outperform rating and $10.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS).
The analyst comments "Solid ZTALMY growth as we look to key Phase 3 TSC results by mid-4Q24; we reiterate our Market Outperform rating and $10 risk-adjusted,... More
Truist Securities Reiterates Buy Rating on Marinus Pharmaceuticals (MRNS)
August 13, 2024 4:04 PM EDTTruist Securities analyst Joon Lee reiterated a Buy rating and $10.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS).
The analyst comments "2Q24: Ph3 TrustTSC trial remain on track for topline in late Oct/early Nov. Low discontinuation rate of... More
